Abstract | AIM: METHODS: RESULTS: A total of 65 patients were evaluated (31 received carboplatin/ vinorelbine, 34 carboplatin/ paclitaxel). The overall response rate was 67.7 % (95% confidence interval [CI]: 56.3-79.1 %) with downstaging in 52.3 % (95% CI: 40.2-64.5 %) and no significant differences between regimens. Median follow-up was 86 months: median overall survival (OS) was 32.1 months (95% CI: 7.4-46.5), median time to progression was 25.1 months (95% CI: 15.1-34.9 months) and five-year overall survival was 35.7 % (95% CI: 23.7-47.7 %). Forty-seven patients (72.3 %) underwent surgery and 43 patients received adjuvant chemotherapy. Five-year survival after tumor resection was 49.5 % (95% CI: 34.2-64.8%), median OS was 59.0 months (95% CI: 34.2-83.1) and median disease free survival after surgery was 57.3 months (95% CI: 29.5-84.4). With MTT-directed therapy, median OS was 85.1 months (95% CI: 15.4-148.6) and the 5-year survival rate was 57.0 % (95% CI: 34.5-79.5 %); the trend for longer survival failed to reach statistical significance. CONCLUSIONS:
|
Authors | Vitezslav Kolek, Ivona Grygarkova, Marian Hajduch, Jiri Klein, Karol Cwiertka, Cestmir Neoral, Katerina Langova, Vladimir Mihal |
Journal | Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
(Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub)
Vol. 152
Issue 2
Pg. 259-66
(Dec 2008)
ISSN: 1804-7521 [Electronic] Czech Republic |
PMID | 19219217
(Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Vinblastine
- Carboplatin
- Paclitaxel
- Vinorelbine
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Carboplatin
(administration & dosage)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality, surgery)
- Chemotherapy, Adjuvant
- Drug Resistance, Neoplasm
- Female
- Humans
- Lung Neoplasms
(drug therapy, mortality, surgery)
- Male
- Middle Aged
- Neoadjuvant Therapy
- Paclitaxel
(administration & dosage)
- Survival Rate
- Vinblastine
(administration & dosage, analogs & derivatives)
- Vinorelbine
|